Telix Pharmaceuticals signs collaborative development and reseller deal with GE Healthcare

Telix Pharmaceuticals Limited (ASX: TLX) signed a collaborative development and reseller deal with GE Healthcare to supply its investigational positron emission tomography imaging radiotracers, TLX250-CDx (89Zr-DFO-girentuximab), and [ 18F]-FLac (18F-3-fluoro-2-hydroxypropionate) for usage in 3rd party clinical research as well as development activities.

The new contract adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio. It will allow patient selection as well as monitoring in immunotherapy trials.

These novel tracers offer the capacity to provide vital info about the metabolic environment of tumours, which might assist to apprise and improve therapy selection.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au